Chan Soon-shiong Nanthealth Foundation

What it reported doing in 2024

The organization is directly engaged in the continuous active conduct of medical research in conjunction with various clinical settings and hospitals. Initially, the organization was engaged in a joint effort with providence saint john's health center to conduct research and development of personalized molecular medical therapies for the treatment of unmet medical needs. Currently, the organization is engaged in joint efforts with windber hospital and johns hopkins university to conduct parallel research and development. The organization provides funding, data and expertise and performs support services including, without limitation, custom engineering, regulatory and medical support services for each project conducted through its joint efforts with windber hospital and johns hopkins university. The organization also plans to conduct medical research projects in collaboration with various universities, particularly research projects led by faculty of the university of California and partner institutions. The organization will annually expend funds equal to 3.5% or more of the fair market value of its endowment for the continuous conduct of medical research or will devote more than one half of its assets to the continuous conduct of medical research. The organization has contracted with chan soon-shiong institute of molecular medicine at windber to study the longer term effects of covid-19 in breast cancer patients. The study involves over 400 participants. Breast cancer is a common cancer in women with 685,000 worldwide deaths in the year 2020 alone. Approximately 30% of all new female cancers are breast cancer. Many of the established risk factors are linked to estrogens. Risk is increased by beginning menstruation at a young age, entering menopause later in life, and obesity in postmenopausal women. The physiological environment that stimulates somatic cells proliferation and differentiation leading to carcinoma are not well understood. The relationship between inflammation and cancer is emerging. Inflammatory diseases increase the risk of developing cancer. Plasma from participants in the study who had covid-19 or not will be utilized to understand the anti-inflammatory immune response in patients with previous breast cancer diagnosis and compare with participants with no previous cancer diagnosis (controls). The hypothesis is that the increased immune response to covid-19 results in a chronic immune response in the breast changing the microenvironment from at th1 response to a th2 response which results in more aggressive breast cancer. The study is ongoing and the findings will be published upon completion.

Financial Efficiency

• Mission deployment rate: 100%; rating input score 100
• Program expense ratio: 95.9%; rating input score 96
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
• Pay-setting controls: 0 of 6 controls in place; rating input score 0
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Missing
• Foreign activity oversight: Limited
• Grant itemization coverage: 100%; rating input score 100; 80th percentile among comparable filings
• Major donor itemization: Limited
• Related-party transparency: Limited

Accountability

• Independent voting board: 50%; rating input score 50; 20th percentile among comparable filings
• Governance controls: 6 of 8 controls in place; rating input score 75
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: -1,046.2%; rating input score 5; 5th percentile among comparable filings
• Total-asset coverage ratio: 29.86; rating input score 86; 86th percentile among comparable filings
• Liabilities to assets ratio: 0.02; rating input score 26; 26th percentile among comparable filings
• Officer compensation ratio: 44.5%; rating input score 8; 8th percentile among comparable filings

Growth

• Program expense growth: -30.5% per year; rating input score 0; 11th percentile among comparable filings
• Revenue growth: -29.1% per year; rating input score 0; 14th percentile among comparable filings
• Asset growth: -8.7% per year; rating input score 0; 15th percentile among comparable filings